PHOTO
New appointment reflects the company's growth strategy across the region
Enrique Manzoni brings more than four decades of strategic corporate experience to lead Middle East, Turkey and Africa (META) operations
United Arab Emirates, Dubai – Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced today the appointment of Enrique Manzoni as Country Managing Director. Manzoni will lead the company’s overall operations in the Middle East, Turkey and Africa (META) region based in Dubai, United Arab Emirates.
An expert in identifying new streams for revenue and value creation, Manzoni will oversee the company’s growth and partnership initiatives in various areas across the region, along with driving a structured approach for the human pharma, consumer healthcare and animal health business activities. His strategic skillset will play a key role in strengthening and driving Boehringer Ingelheim’s operations in the META region.
Positioning the company for future growth, he brings more than four decades of solid experience to the region across the corporate, finance, technology, and operations practice areas.
Commenting on his appointment, Enrique Manzoni said, “This is an exciting time for me to be in the region, with the ongoing growth and huge nascent potential in the healthcare and pharma sector. At the same time, regional governments are working towards developing a robust infrastructure and implementing policies to address healthcare concerns towards a better health for their nations.”
“The UAE, in particular, is a fast developing center of world class healthcare facilities, backed by progressive reforms and integrated systems of care, ensuring a business environment for the world’s best brands to grow and establish themselves. Patients have always been at the core of everything we do at Boehringer Ingelheim, and we look forward to building on our established business to continue being a part of the region’s growth story,” added Manzoni.
Prior to joining the META region, Manzoni managed the company’s regional business volume of €700 million in Belgium, Denmark, Finland, Greece, Netherlands, Norway, Portugal and Sweden, in addition to being accountable for four manufacturing facilities.
With a proven history of overachieving financial goals, and expanding the company’s reach, Manzoni has been with Boehringer Ingelheim for more than 28 years, working in various leadership capacities, running various investment portfolios for the company and developing successful operating business models.
The pharmaceutical market in the META region has witnessed considerable progress over the years due to favorable demographic and economic factors, and increased government expidenture for healthcare. Boehringer Ingelheim is well positioned for growth and development across the various markets it operates in.
In 2015, the company’s Middle East and North Africa (MENA) achieved a sales growth of 26%. Moreover, the company’s META operations achieved a growth of 17.4% in its sales, where strong performing markets included Saudi Arabia, Turkey, Egypt, Algeria as well as the United Arab Emirates (UAE).
In the UAE, Boehringer Ingelheim recorded a 34% growth compared to the previous financial year. It also expanded by 65% in terms of number of employees in the UAE within the last four years.
-Ends-
About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.
In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information please visit www.boehringer-ingelheim.com
For more information, please contact:
Emeel Bishay
FleishmanHillard
T: + 971 4450 2600
M: +971 55 886 2717
Emeel.Bishay@fleishman.com
© Press Release 2016
